The results of phototherapy on a small series of 19 patients with uveal melanomas are presented. Laser radiation at a wavelength of 620 to 630 nm was used in conjunction with a 5 to 7 5 mg/kg dose ofhaematoporphyrin derivative administered 24 hours before treatment, with total doses/treatment averaging 960 J/cm'. Eleven patients received two treatments, and one received a third. The longest duration of tumour control to 30 September 1990 was 31 months. Of the 19 patients treated six had complete regression of the tumour, while another five had minor to significant regression. A strong correlation between degree of regression and degree of tumour pigmentation was found, the lighter tumours responding much better than darker tumours. There were also strong indications that if a tumour did not respond to the initial phototherapy it was very unlikely that subsequent phototherapy would provide any further benefit.
For over a hundred years enucleation has been the traditional method of treatment for posterior uveal melanomas, particularly for large tumours. However, its singular lack of success in increasing life expectancy' has led to alternative methods of treatment, with radiotherapy being the most effective and widely used.2" Since recent reports have shown that enucleation and radiotherapy have essentially equivalent survival rates," new forms of therapy such as phototherapy need to be evaluated.
Phototherapy (PT) has been shown to destroy implanted melanomas and retinoblastomas in animals, with few adverse effects.89 The operation of PT is based on the fact that malignant tissue selectively retains a photosensitiser such as haematoporphyrin derivative (HpD) . If the sensitiser is subsequently activated with light of an appropriate wavelength, it releases highenergy radicals which cause tumour cell destruction.'0 Although the use of light-sensitive substances in the treatment of disease was described as early as 4000 BC,"I it was first used successfully to treat basal cell carcinomas in 1905. 12 Since then it has been used to treat many different forms of cancer with varying degrees of success and with minimal side effects. '3 14 The few reports of phototherapy for posterior uveal melanomas in humans have been encouraging, despite the small numbers, short follow-up, and varied response. In one series seven posterior uveal melanomas were treated with one complete response in an amelanotic melanoma of 9-4 mm height at the posterior pole followed up for four years, with varied to zero response in the others. '5 In another report, of 23 patients, the greatest tumour reduction occurred in melanomas of less than 1000 cm3 volume, with no adverse systemic side effects from HpD. '6 Marked necrosis extending to the base of the melanoma has been reported in enucleated specimens following PT. 17 HpD has been the photosensitiser most widely used. It binds tightlyto serum proteins, including lipoprotein carriers, and there is a linear relationship between cell volume and uptake.'I Animal experiments have shown that it localises in vascular structures of the eye (choroid, iris, retina) within 48 hours of intravenous administration, with lower concentrations in the sclera, and with none located within the cornea and lens. '9 In experimental tumours it is concentrated in the vascular stroma (macrophages, mast cells, and possibly fibroblasts), with a lower concentration in the cells, and the earliest histological change following PT is bleeding of tumour cells adjacent to the microvasculature.2' The actual mechanism by which tumour cells are destroyed is not clear, though ischaemia,2122 destruction of cell membrane functions, intracellular enzyme inhibition, and DNA damage probably initiated by singlet oxygen production" and other radicals have been reported.24 Ocular toxicity studies have shown that its acute effects are confined to the treated area, and the chronic changes are non-progressive. ' Patients were treated with a pulse-injected second treatments, were enucleated. Histopathology, including transmission electron microscopy, showed active tumour cell growth in all eyes with extrascleral extension in one (patient 9). Table 2 lists Spearman's rank correlation coefficients and significance levels for the relationship between degree of regression with tumour height, volume, initial and cumulative PT doses, and degree of pigmentation. There was no significant correlation with height, volume, or initial PT dose. Cumulative dose showed a strong negative correlation with degree ofregression, which implies that ifa tumour does not respond to initial PT it probably will not respond to further treatment. Very strong correlation was found between degree of regression and degree of pigmentation; the less the pigmentation, the greater the degree of regression.
Discussion
Despite the small size of this series the shortterm results following PT were encouraging. The lack of correlation between tumour response and its physical attributes, apart from the degree of pigmentation, highlights the unpredictability of the PT response owing to multiple factors including photosensitiser type, dosimetry and tissue uptake, and the total dose of light energy. Although HpD is the most commonly used sensitiser for PT, it is not ideal. It maximally absorbs light at 390 nm wavelength; but because this wavelength has poor tissue penetration, the minor absorption peak at 630 nm wavelength, which penetrates tissues more effectively, but requires relatively more energy, is generally used. The 
